Tibet Weixinkang Medicine Co., Ltd.

603676

CNE100002QQ3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
9.05 ^CNY	-0.22%		-4.23%	-13.23%

05-06	Tibet Weixinkang Medicine's Unit Gets Nod for Potassium Aspartate Injection's Production	MT
04-25	Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tibet Weixinkang Medicine Co., Ltd. Announces Earnings Results for the First Quarter of 2019

April 24, 2019

Tibet Weixinkang Medicine Co., Ltd. announced earnings results for the first quarter of 2019. Basic earnings per share were CNY 0.05.

Latest news about Tibet Weixinkang Medicine Co., Ltd.

Tibet Weixinkang Medicine's Unit Gets Nod for Potassium Aspartate Injection's Production	05-06	MT
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23	CI
Tibet Weixinkang Medicine Co., Ltd.(XSSC:603676) added to S&P Global BMI Index	18/09/23	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	22/08/23	CI
Tibet Weixinkang Medicine Unit Gets Certification for Dopamine Drug in China	30/06/23	MT
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22/08/22	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	28/04/22	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	28/10/21	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	17/08/21	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the First quarter Ended March 31, 2021	28/04/21	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	28/04/21	CI
Zhejiang China Commodities City : China stocks end higher on upbeat data	28/12/20	RE
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	28/10/20	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	26/08/20	CI
Certain A Shares of Tibet Weixinkang Medicine Co., Ltd. are subject to a Lock-Up Agreement Ending on 21-JUL-2020.	20/07/20	CI
Tibet Weixinkang Medicine Co., Ltd. Announces Implementation of Rights and Interests Distribution Per A Share for 2019, Payable on June 2, 2020	25/05/20	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	27/04/20	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019	24/10/19	CI
Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	27/08/19	CI
Tibet Weixinkang Medicine Co., Ltd. Announces Implementation of Rights and Interests Distribution for 2018, Payable on May 30, 2019	22/05/19	CI
Tibet Weixinkang Medicine Co., Ltd. Announces Earnings Results for the First Quarter of 2019	24/04/19	CI

Chart Tibet Weixinkang Medicine Co., Ltd.

Duration

Period

Chart Tibet Weixinkang Medicine Co., Ltd.

More charts

Tibet Weixinkang Medicine Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical medicines and related active pharmaceutical ingredients (APIs). The Company's main products include injection of complex vitamins, injection of potassium aspartate magnesium, sucrose iron injection and potassium aspartate injection. The Company is also engaged in the production and sales of liver protection drugs and antibiotics products. The Company mainly distributes its products in the domestic market.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
TIBET WEIXINKANG MEDICINE CO., LTD.	-13.23%	544M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.04%	42.95B
OTSUKA HOLDINGS CO., LTD.	+16.92%	21.38B
SANDOZ GROUP AG	+18.33%	15.05B
CIPLA LIMITED	+19.27%	14.45B
ZYDUS LIFESCIENCES LIMITED	+56.12%	13.04B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.73%	6.72B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+11.21%	5.47B